At $10 cap will be around $200m.still reasonable relating market potential,imo. The FDA already granted a Fast Track status to CA4P. Very solid balance sheet,trading way under Net Assets.
OXGN to hit two birds with one stone,awesome: https://biz.yahoo.com/e/160602/oxgn8-k.html. (shareholders wouldn't have voted to no R/S if weren't pretty sure it wouldn't be necessary imo,Catalyst this month).